The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 \[NCT00076011\] study to estimate the 5-year survival rate in subjects with metastatic renal cancer cell treated with axitinib.
Subjects participating in this observational study originally participated in study A4061012 \[NCT00076011\], and may have also have participated in study A4061008 \[NCT00828919\]. Subjects participating in this observational study originally participated in study A4061012 \[NCT00076011\], and may have also have participated in study A4061008 \[NCT00828919\]. 5-year survival information to be updated.
Study Type
OBSERVATIONAL
Enrollment
52
Non-interventional observational study
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
New York, New York, United States
Overall Survival (OS)
Overall survival is the duration from first dose of study medication to death. For participants who are alive, overall survival is censored at the last contact.
Time frame: Baseline until death or up to Year 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Madison, Wisconsin, United States
Pfizer Investigational Site
Paris, France
Pfizer Investigational Site
Hanover, Germany